Roquefort Therapeutics Income Statement

Financials in millions GBP. Fiscal year is January - December.

Millions GBP. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	-	-	0.2	-	0
Other Revenue	-	-	-	-	0
Revenue	-	-	0.2	-	0
Cost of Revenue	-	0.02	-	-	0.01
Gross Profit	-	-0.02	0.2	-	-0.01
Selling, General & Admin	0.75	0.94	1.51	1.31	0.38
Research & Development	0.18	0.15	0.62	0.32	0
Operating Expenses	0.93	1.1	2.13	1.63	0.38
Operating Income	-0.93	-1.12	-1.93	-1.63	-0.38
Interest Expense	-0.05	-0.04	-0	-	-
Interest & Investment Income	-	-	0	-	-
Other Non Operating Income (Expenses)	-0.06	-0.05	-	-	-0.14
EBT Excluding Unusual Items	-1.04	-1.21	-1.93	-1.63	-0.52
Merger & Restructuring Charges	-	-	-	-	-0.17
Pretax Income	-1.04	-1.21	-1.93	-1.63	-0.69
Income Tax Expense	-0.16	-0.24	-0.19	-0.02	-
Net Income	-0.88	-0.97	-1.74	-1.62	-0.69
Net Income to Common	-0.88	-0.97	-1.74	-1.62	-0.69
Shares Outstanding (Basic)	139	130	130	103	25
Shares Outstanding (Diluted)	139	130	130	103	25
Shares Change (YoY)	4.18%	-	25.66%	318.92%	-
EPS (Basic)	-0.01	-0.01	-0.01	-0.02	-0.03
EPS (Diluted)	-0.01	-0.01	-0.01	-0.02	-0.03
Free Cash Flow	-0.65	-0.78	-1.79	-1.58	-0.39
Free Cash Flow Per Share	-0.01	-0.01	-0.01	-0.01	-0.02
Gross Margin	-	-	100.00%	-	-
Operating Margin	-	-	-966.82%	-	-60121.98%
Profit Margin	-	-	-872.27%	-	-108018.05%
Free Cash Flow Margin	-	-	-893.79%	-	-60851.65%
EBITDA	-0.93	-1.11	-1.93	-	-
D&A For EBITDA	0.01	0.01	0	-	-
EBIT	-0.93	-1.12	-1.93	-1.63	-0.38

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.